Systematic review of 20 studies (2551 patients) of T-cell-engaging bispecific antibodies in NHL or myeloma: pooled second primary malignancy rate 3.5% (8 studies, 1003 patients) at median 17.4 months; 1.4% led to death (19 studies).
Meta-analysisn = 2,551
Tomasik et al. Second Primary Malignant Neoplasms After T-Cell-Engaging Bispecific Antibody Therapy: A Systematic Review and Meta-Analysis